2. Academic Validation
  3. FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

FXR agonists for colorectal and liver cancers, as a stand-alone or in combination therapy

  • Biochem Pharmacol. 2023 Apr 27;115570. doi: 10.1016/j.bcp.2023.115570.
Danmei Yu 1,  Zhou Lu 2,  Ruyu Wang 1,  Yusen Xiang 1,  Hongtao Li 1,  Jiani Lu 1,  Lijun Zhang 1,  Hongzhuan Chen 1,  Weihua Li 2,  Xin Luan 3,  Lili Chen 4
Affiliations

Affiliations

  • 1 Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
  • 2 Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shanghai 200237, China.
  • 3 Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: [email protected].
  • 4 Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address: [email protected].
PMID: 37119860 DOI: 10.1016/j.bcp.2023.115570
Abstract

Farnesoid X receptor (FXR, NR1H4) is generally considered as a tumor suppressor of colorectal and liver cancers. The interaction between FXR, bile acids (BAs) and gut microbiota is closely associated with an increased risk of colorectal and liver cancers. Increasing evidence shows that FXR agonists may be potential therapeutic agents for colorectal and liver cancers. However, FXR agonists alone do not produce the desired results due to the complicated pathogenesis and single therapeutic mechanism, which suggests that effective treatments will require a multimodal approach. Based on the principle of improvingefficacy andreducingside effects, combination therapy is currently receiving considerable attention. In this review, colorectal and liver cancers are grouped together to discuss the effects of FXR agonists alone or in combination for combating the two cancers. We hope that this review will provide a theoretical basis for the clinical application of novel FXR agonists or combination with FXR agonists against colorectal and liver cancers.

Keywords

Bile acids; Colorectal cancer; Combination therapy; FXR agonists; Gut microbiota; Liver cancer.

Figures
Products